Sort
4,870 grants matching “glp 1”
Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent
$715,674Mykhaylo Dukh · Photolitec, Llc · R42 · FY2015 · CA
B. thuringiensis crystal proteins as powerful next-generation anthelmintics
$715,337Raffi V Aroian · Univ Of Massachusetts Med Sch Worcester · R01 · FY2025 · AI
Final preclinical development of an immunoadhesin therapy for inhalation anthrax
$715,128Keith Wycoff · Planet Biotechnology, Inc. · R01 · FY2013 · AI
PASSIVE IMMUNITY TO COCAINE USING NOVEL HUMAN ANTIBODIES
$715,114University Of Cincinnati · U19 · FY2000 · DA
Virtual systemic identification of drug targets of obesity candidate genes
$714,892Yingchang Lu · Vanderbilt University Medical Center · R01 · FY2024 · DK
Optimization of a Combined Drug and Delivery Device for Treatment of Cyanide Poisoning
$713,862Zhengqiang Wang · University Of Minnesota · U01 · FY2023 · NS
Development of Filociclovir for the Treatment of Ocular Adenoviral Infections and Keratoconjunctivitis
$712,798Terry L Bowlin · Microbiotix, Inc · R44 · FY2022 · EY
Advancing a Lead Candidate Hantavirus Pulmonary Syndrome DNA Vaccine
$712,297Jay Williams Hooper · Geneva Foundation · R01 · FY2015 · AI
Developing autologous iPSC-RPE based IND for AMD patients
$712,226Kapil Bharti · National Eye Institute · ZIA · FY2015 · EY
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans with Prediabetes
$711,461Absalon Dennis Gutierrez · University Of Texas Hlth Sci Ctr Houston · R01 · FY2021 · DK
Developing A Novel Therapy for Diabetic Retinopathy
$710,237Danyang Chen · Charlesson, Llp · R44 · FY2016 · EY
Enhancement of Beta Cell Function with Pharmacologic and Sleep Apnea Treatment
$709,717David A Ehrmann · University Of Chicago · U01 · FY2011 · DK
Evaluation of a Robotic Assisted Surgical System for Hearing Loss
$709,641Allan Henslee · Iotamotion, Inc. · R44 · FY2017 · DC
Cardiovascular effects of GLP-1 in obesity/metabolic syndrome
$709,525Johnathan D Tune · Indiana University Indianapolis · R01 · FY2014 · HL
3D Printed Airway Splints: Pre-clinical and Clinical In Vivo Degradation and Tissue Response
$709,172Scott J Hollister · Georgia Institute Of Technology · R01 · FY2025 · HL
Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis
$709,043James Craig Hartman · Mdi Therapeutics, Inc. · R44 · FY2023 · HL
Neuroprotective And Neurorestorative Signaling Mechanisms
$709,016Mark Mattson · National Institute On Aging · ZIA · FY2010 · AG
Development of a Counterpulsation Therapy Device
$708,881Paul A Spence · Scr, Inc. · R44 · FY2008 · HL
Regulation of the biosynthesis of a novel class of anti-diabetic lipids
$707,327Barbara B Kahn · Beth Israel Deaconess Medical Center · R01 · FY2019 · DK
Regulation of the biosynthesis of a novel class of anti-diabetic lipids
$707,327Barbara B Kahn · Beth Israel Deaconess Medical Center · R01 · FY2020 · DK
Regulation of the biosynthesis of a novel class of anti-diabetic lipids
$707,327Barbara B Kahn · Beth Israel Deaconess Medical Center · R01 · FY2017 · DK
Optimization of Substituted Phenoxyalkyl Pyridinium Oximes as Therapies for Organophosphate Poisoning
$706,875Janice E. Chambers · Mississippi State University · U01 · FY2021 · NS
Treatment of Transplant Reperfusion with CD47 antibody
$706,733Pamela Ann Toy-Manning · Vasculox, Inc. · R44 · FY2012 · HL
Development of RNAi based sFLT1-targeting therapeutics for treatment of Preeclampsia
$706,386Anastasia Khvorova · Univ Of Massachusetts Med Sch Worcester · R01 · FY2016 · HD
Large animal therapy studies
$706,283William A. Beltran · University Of Pennsylvania · R24 · FY2015 · EY